Study of Amide Proton Transfer-Weighted Imaging to Predict Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer

What this Trial Is About

Researchers are studying how amide proton transfer-weighted imaging APTWI, a special MRI technique, can help predict how rectal cancer responds to treatment before surgery. The study focuses on patients with locally advanced rectal cancer who have received neoadjuvant therapy, aiming to see if this imaging method can foresee a complete pathological response. This observational study is sponsored by the Sixth Affiliated Hospital, Sun Yat-sen University and collects data as part of regular MRI exams. Participants undergo amide proton transfer-weighted imaging as part of their routine MRI scans before surgery. The study examines the imaging results between the baseline MRI and the preoperative MRI, which should be within 12 months. Researchers analyze how well APTWI predicts tumor response, measuring accuracy, sensitivity, specificity, and predictive values. They also monitor disease-free and overall survival for up to 60 months after enrollment. During the study, participants MRIs are reviewed to assess tumor response to prior therapy. Researchers evaluate the imagings ability to predict outcomes and compare it to pathological results after surgery. The primary outcome is the area under the curve AUC of prediction models within 12 months, with additional measures including survival outcomes. Participants are followed for up to 5 years, with data collected from regular MRI exams and clinical records.

Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer